Reading time: 11 minutes

Cancer early detection is a high-noise commercial space. Marketing for “one tube of blood detects 50 cancers” or “ultra-early ctDNA methylation screening” is everywhere, but the majority of multi-cancer early detection (MCED) products still lack high-quality evidence that they change long-term survival [1][2]. This article takes a deliberately restrained position and distinguishes three categories: screening with solid evidence recommended by international authorities (USPSTF / NCCN / ACS); screening with some evidence requiring individual discussion; and screening still under research that should not yet be treated as standard practice. Every statement is anchored in publicly available evidence; no specific product is promoted.

1. Screening With Solid Evidence and Authoritative Recommendation (by Cancer Type)

Cancer Recommended screening Recommended population Source
Colorectal cancer Colonoscopy (every 10 years) / FIT (annually) / DNA + FIT (every 3 years) 45–75 years USPSTF [3]
Breast cancer Mammography Women 40–74 (cutoffs vary by guideline) USPSTF / ACS
Cervical cancer Cytology ± HPV testing Women 21–65 USPSTF
Lung cancer Low-dose chest CT (annually) 50–80 years, ≥ 20 pack-year smoking history, quit < 15 years USPSTF [4]
Prostate cancer PSA (shared decision) Men 55–69 USPSTF
Gastric cancer (high-incidence regions) Gastroscopy + H. pylori testing High-risk individuals (family history, East Asian) National Cancer Center of China / regional guidelines
Hepatocellular carcinoma (high-risk individuals) Abdominal ultrasound + AFP (every 6 months) Chronic hepatitis B, cirrhosis AASLD / EASL [5]

This is the baseline of any screening discussion — any “premium package” should satisfy these core items first.

2. Items With Some Evidence — Individual Discussion Required

Item When to consider
BRCA1/2 genetic testing Family history of breast or ovarian cancer
Lynch syndrome gene panel Family history of colorectal, uterine, or early-onset cancer
Coronary artery calcium (CAC) — see Article #75 Intermediate cardiovascular risk
Chest CT in non-smokers Some Chinese guidelines support consideration in lower-risk populations (slightly different from USPSTF); individualised
Whole-body MRI for specific genetic syndromes such as Li-Fraumeni TP53 mutation carriers
Gastroscopy in general populations outside high-incidence regions Driven by individual symptoms or family history

3. Items Still Under Research — Not Yet Standard Screening (Plain Disclosure)

Item Current status
Multi-cancer early detection MCED (ctDNA / methylation panels) US products including Galleri, Exact Sciences, and Guardant remain under large RCT evaluation for mortality endpoints; the FDA has not approved any MCED as a population screening tool [1][6]
Domestic Chinese ctDNA / methylation early-detection products Commercially available but mostly lacking prospective mortality-endpoint evidence
Whole-body PET-CT as a health check Not recommended as asymptomatic screening by any major guideline
Whole-body MRI as a health check High incidentaloma rate; evidence does not support routine use
Full tumour marker panels (CEA, CA125, CA19-9, etc.) Not recommended as screening [7]
“Liquid biopsy + AI algorithm” healthy-individual multi-cancer screening Lacks RCT evidence; should not drive clinical decisions

A direct view on multi-cancer early detection MCED:

  1. This is a field still under evaluation — academically promising but without mortality-endpoint evidence
  2. False-positive rates and “lesion found but not localised” challenges are real
  3. Data from the NHS-Galleri trial in England are expected to be released progressively from around 2026
  4. At present, MCED is appropriate for patients who explicitly want it and understand its uncertainty — it should not replace standard screening

4. Standard Cancer Screening Resources Available in China

Colorectal / lung / gastric: see Article #66 and #71; coverage at leading Chinese hospitals is extensive Breast / cervical: standard offerings at general hospital gynaecology and breast surgery departments Liver cancer: standard follow-up at chronic hepatitis centres and hepatobiliary surgery departments

5. Typical Process (Evidence-Based Screening Package Concept)

50-year-old male with 25 pack-year smoking history, no family history — standard screening package (2–3 days):

  1. Day 1: clinical evaluation + lipid panel + glucose + HbA1c
  2. Day 1: chest LDCT + coronary calcium score
  3. Day 2: gastroscopy + colonoscopy (same day, under sedation)
  4. Day 3: report review and action plan

6. Typical Costs (USD, 1 USD = 6.5 RMB)

Item Public tertiary international dept. High-end private
Complete standard screening package (colonoscopy + gastroscopy + LDCT + basic biochemistry) 800–1,800 1,500–3,500
+ mammography + cervical cytology + HPV + 250–600 + 400–900
+ BRCA / Lynch panel + 350–800 + 500–1,200
+ CAC + 200–500 + 400–800
Multi-cancer early detection MCED product (domestic Chinese) 800–2,500 1,000–3,500
Whole-body PET-CT (not recommended as screening) 1,500–3,000 2,500–4,500
Whole-body MRI (not recommended as screening) 1,200–2,500 2,000–4,000

7. What MedCareInChina Can and Cannot Do on the Cancer Screening Pathway

Our two products are Remote Consultation and In-China Accompanied Care.

  1. Remote Consultation: USD 800 single-expert consultation. An oncology or general physician can help you design a sensible screening plan (so that high-cost packages do not drive the decision); abnormal findings can be discussed remotely
  2. In-China Accompanied Care: full accompaniment and translation through screening, endoscopy, and imaging

What we do not do: promote any specific MCED product; offer “comprehensive cancer rule-out” guarantees.

8. Action Checklist

  1. Use age and risk factors to map your standard screening items against Section 1
  2. Be selective about Section 2 items requiring individual discussion
  3. Do not let “whole-body scan + multi-cancer early detection” marketing drive your plan
  4. Engage a remote consultation to validate a sensible plan
  5. Apply for an S2 visa
  6. Plan 2–3 days in China
  7. Any abnormal finding → joint decision-making between your home physician and the Chinese specialist

Sources

[1] National Cancer Institute — Multi-Cancer Early Detection (MCED) research overview: https://www.cancer.gov/ [2] US Preventive Services Task Force — Cancer screening recommendations master list: https://www.uspreventiveservicestaskforce.org/ [3] USPSTF — Colorectal Cancer Screening [4] USPSTF — Lung Cancer Screening [5] AASLD — Hepatocellular Carcinoma Surveillance Guidelines: https://www.aasld.org/ [6] NHS England — Galleri trial public information: https://www.nhs-galleri.org/ [7] American Society of Clinical Oncology — Tumor marker guidelines: https://www.asco.org/